Trial reportClinical chemistry2009
Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.
Trial report in Clinical chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.Therapeutic drug monitoring · 2011Trial
- An Individualized, Interdisciplinary Approach to the Perioperative Care of Patients on Buprenorphine.Current pain and headache reports · 2026Review
- The Pharmacological Treatment of Chronic Pain: From Guidelines to Daily Clinical Practice.Pharmaceutics · 2023Review
- Investigation of buprenorphine-related deaths using urinary metabolite concentrations.Drug testing and analysis · 2022Article
- Clearance of buprenorphine during pregnancy and neonatal outcomes.Archives of women's mental health · 2021Observational
- Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum.Current treatment options in psychiatry · 2020Article
- Opioid use disorder in pregnancy.The mental health clinician · 2019Article
- Effects of opioids on the parental brain in health and disease.Frontiers in neuroendocrinology · 2019Review
- Neonatal abstinence syndrome.Nature reviews. Disease primers · 2018Review
- Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation.Drug metabolism and disposition: the biological fate of chemicals · 2018Article
- Use of an Acetyl Derivative to Improve GC-MS Determination of Norbuprenorphine in the Presence of High Concentrations of Buprenorphine in Urine.Journal of analytical toxicology · 2016Article
- Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?SpringerPlus · 2016Article
- Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.Addiction (Abingdon, England) · 2012Review
- Pharmacogenomics of buprenorphine - a narrative review.PharmacogenomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundBuprenorphine (BUP) is under investigation as a medication therapy for opioid-dependent pregnant women. We investigated BUP and metabolite disposition in urine from women maintained on BUP during the second and third trimesters of pregnancy and postpartum.
methodsWe measured BUP, norbuprenorphine (NBUP), buprenorphine glucuronide (BUP-Gluc), and NBUP-Gluc concentrations in 515 urine specimens collected thrice weekly from 9 women during pregnancy and postpartum. Specimens were analyzed using a fully validated liquid chromatography-mass spectrometry method with limits of quantification of 5 microg/L for BUP and BUP-Gluc and 25 microg/L for NBUP and its conjugated metabolite. We examined ratios of metabolites across trimesters and postpartum to identify possible changes in metabolism during pregnancy.
resultsNBUP-Gluc was the primary metabolite identified in urine and exceeded BUP-Gluc concentrations in 99% of specimens. Whereas BUP-Gluc was identified in more specimens than NBUP, NBUP exceeded BUP-Gluc concentrations in 77.9% of specimens that contained both analytes. Among all participants, the mean BUP-Gluc:NBUP-Gluc ratio was significantly higher in the second trimester compared to the third trimester, and there were significant intrasubject differences between trimesters in 71% of participants. In 3 women, the percent daily dose excreted was higher during pregnancy than postpregnancy, consistent with other data indicating increased renal elimination of drugs during pregnancy.
conclusionsThese data are the first to evaluate urinary disposition of BUP and metabolites in a cohort of pregnant women. Variable BUP excretion during pregnancy may indicate metabolic changes requiring dose adjustment during later stages of gestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.